Department of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, Athens, Greece.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Cardiovasc Pathol. 2019 May-Jun;40:7-11. doi: 10.1016/j.carpath.2018.12.008. Epub 2019 Jan 3.
Cardiac iron overload following liver transplantation in patients without hemochromatosis but with severe hepatic iron deposition has been reported to result in heart failure and/or death in case reports and small case series. However, the frequency and causes of cardiac iron overload following liver transplantation and its relationship to cardiac dysfunction in patients without severe hepatic iron deposition are unclear.
The primary inclusion criteria for this study were liver transplantation followed by autopsy or cardiac transplantation within 1 year. Cases of known hemochromatosis were excluded. Iron stains were performed on left ventricular myocardium from either the autopsy or surgically resected heart, as well as the surgically resected liver.
Nineteen cases met the study criteria: 18 autopsies and 1 case of cardiac transplantation. None of the resected livers evaluated showed severe iron deposition. Myocardial iron deposition was identified in 7 (37%) of the cases. The presence of myocardial iron deposition was not significantly associated with the grade of hepatic iron deposition, or the pre-liver transplantation serum iron or ferritin levels. However, in the patients with myocardial iron deposition, there were trends toward higher pretransplant transferrin saturation (TSAT) and more units of red blood cells transfused (uRBC). The product of the TSAT multiplied by the uRBC was significantly greater in the patients with myocardial iron deposition [4700 (3100-9800) vs. 680 (400-2300), median (interquartile range), P=.003]. New reduced left ventricular ejection fraction (<50%) following liver transplantation occurred in four of five patients with myocardial iron deposition, compared with zero of eight patients without myocardial iron deposition (P=.007).
In this series of patients without severe hepatic iron deposition, cardiac iron overload was associated with cardiac dysfunction following liver transplantation and was related to the product of the pre-liver transplant TSAT multiplied by the number of uRBC transfused during and following the surgery.
在没有血色病但肝铁沉积严重的患者中,肝移植后发生心脏铁过载可导致心力衰竭和/或死亡,这在病例报告和小病例系列中已有报道。然而,肝移植后心脏铁过载的频率和原因以及其与无严重肝铁沉积患者的心脏功能障碍的关系尚不清楚。
本研究的主要纳入标准是肝移植后 1 年内行尸检或心脏移植。排除已知血色病的病例。对尸检或手术切除的心脏以及手术切除的肝脏的左心室心肌进行铁染色。
19 例符合研究标准:18 例尸检和 1 例心脏移植。评估的所有切除肝脏均未见严重铁沉积。7 例(37%)患者存在心肌铁沉积。心肌铁沉积的存在与肝铁沉积程度、肝移植前血清铁或铁蛋白水平无显著相关性。然而,在存在心肌铁沉积的患者中,移植前转铁蛋白饱和度(TSAT)和红细胞输注单位(uRBC)更高,呈趋势性。心肌铁沉积患者的 TSAT 与 uRBC 的乘积显著大于无心肌铁沉积患者[4700(3100-9800)比 680(400-2300),中位数(四分位距),P=.003]。4 例存在心肌铁沉积的患者在肝移植后新发左心室射血分数降低(<50%),而 8 例无心肌铁沉积的患者无一例新发左心室射血分数降低(P=.007)。
在本系列无严重肝铁沉积的患者中,心脏铁过载与肝移植后心脏功能障碍有关,与肝移植前 TSAT 与手术期间和手术后 uRBC 输注量的乘积有关。